End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁 3/12/2026
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Most Promising Future Hair Loss Treatments In 2026
Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community Is it a safe bet to say that hair cloning will be available in the next 30 years?
Hair cloning might be available in 10-15 years, but current and upcoming treatments like finasteride, dutasteride, and new drugs like g20029 may make it unnecessary. Advances in hair regrowth technology and treatments are expected to be more cost-effective and accessible.
community Desensitize Follicle Sensitivity to DHT?
Hair follicles cannot be desensitized to DHT like allergies; treatments focus on reducing DHT levels or blocking its effects using methods like finasteride, GT20029, or PROTACs. Topical treatments like ceterizine and BPA application are also mentioned.
Related Research
6 / 6 resultsresearch Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.
research PROTACs in 2025: from the laboratory concept to clinical breakthrough
This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.